PMGC Stock (NASDAQ:ELAB)


RevenueOwnershipFinancialsChart

Previous Close

$0.91

52W Range

$0.84 - $309.89

50D Avg

$1.30

200D Avg

$35.63

Market Cap

$1.91M

Avg Vol (3M)

$2.98M

Beta

-0.24

Div Yield

-

ELAB Company Profile


PMGC Holdings Inc. functions as a biopharmaceutical firm, primarily dedicated to sourcing and advancing innovative aesthetic and therapeutic solutions. Its flagship product, EL-22, is a pioneering engineered probiotic designed to tackle the critical challenge of maintaining muscle mass during weight reduction regimens, especially those utilizing GLP-1 receptor agonists. Beyond its core operations, the company also engages in medical scientific research and development and manages various investment firms. Formerly known as Elevai Labs, Inc., the organization adopted its current name, PMGC Holdings Inc., in December 2024. Established in 2020, PMGC Holdings Inc. maintains its headquarters in Newport Beach, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

34

IPO Date

Nov 21, 2023

Website

ELAB Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23
AUSTRIA$234.80K
CANADA$158.60K
UNITED STATES$1.71M
VIET NAM$70.66K

Fiscal year ends in Dec 24 | Currency in USD

ELAB Financial Summary


Dec 24Dec 23Dec 22
Revenue-$1.71M$766.28K
Operating Income$-4.02M$-3.67M$-1.79M
Net Income-$-4.30M$-1.80M
EBITDA$-4.02M$-4.27M$-1.78M
Basic EPS-$-0.40$-0.19
Diluted EPS-$-0.40$-0.19

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison


TickerCompany
NCELNewcelX Ltd.
PBMPsyence Biomedical Ltd.
WINTWindtree Therapeutics, Inc.
VRAXVirax Biolabs Group Limited
XRTXXORTX Therapeutics Inc.
DRMADermata Therapeutics, Inc.
MLECMoolec Science S.A.